このエントリーをはてなブックマークに追加
ID 37739
file
creator
Ishioka, Shinichi
Hozawa, Soichiro
Hiyama, Keiko
Maeda, Akihiro
Yamakido, Michio
subject
Bronchial asthma
Cysteinyl leukotriene receptor antagonist
Pranlukast
Serum eosinophil cationic protein
NDC
Medical sciences
abstract
Cysteinyl leukotrienes (cysLTs) are considered to be important mediators involved in bronchial asthma and the ensuing eosinophilic inflammation. We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients. A four-week administration of pranlukast increased the morning peak expiratory flow (PEF) (p=0.007) and decreased as-needed /3z-agonist use (p=0.021). Changes in the morning PEF inversely correlated with those in the serum ECP levels (r=-0.80, p=0.0057). These results suggest that cysLTs are important mediators involved in eosinophilic inflammation, a major pathophysiologic feature of bronchial asthma in humans.
description
Part of this study was supported by a research grant from the Japanese Ministry of Health and Welfare.
journal title
Hiroshima Journal of Medical Sciences
volume
Volume 48
issue
Issue 4
start page
105
end page
110
date of issued
1999-12
publisher
Hiroshima University Medical Press
issn
0018-2052
ncid
language
eng
nii type
Departmental Bulletin Paper
HU type
Departmental Bulletin Papers
DCMI type
text
format
application/pdf
text version
publisher
department
Graduate School of Biomedical Science
他の一覧